文献速递神经免疫

依库珠单抗治疗AQP4-IgG阳性NMOSD的长期安全性与疗效

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
PubMed 文献 · Ann Neurol · 2021-02-27

PREVENT及其开放标签扩展(OLE)研究的中期分析显示,137例AQP4-IgG阳性NMOSD患者接受依库珠单抗治疗中位133.3周,治疗相关不良事件率为183.5/100患者年,严重不良事件率为8.6/100患者年,无脑膜炎球菌感染发生;192周时94.4%患者保持无复发,年化复发率为0.025。

要点

  • 长期依库珠单抗治疗维持低复发风险,192周无复发率94.4%。
  • 治疗相关不良事件与严重不良事件发生率分别为183.5/100PY和8.6/100PY。
  • 严重感染率10.2/100PY,低于安慰剂组的15.1/100PY,无脑膜炎球菌感染。

核心结论

  • 依库珠单抗在AQP4-IgG阳性NMOSD中长期安全性与其他适应症一致,并持续降低复发风险。

研究设计与样本

  • PREVENT及其开放标签扩展(OLE)研究的中期分析,共137例患者接受依库珠单抗治疗,中位监测133.3周,总暴露362.3患者年。

主要发现

  • 治疗相关不良事件率为183.5/100患者年,严重不良事件率为8.6/100患者年。
  • 严重感染率为10.2/100患者年,安慰剂组为15.1/100患者年,无脑膜炎球菌感染。
  • 192周时94.4%(95%CI 88.6-97.3)患者保持无复发。
  • 年化复发率在依库珠单抗组为0.025(95%CI 0.013-0.048),安慰剂组为0.350(95%CI 0.199-0.616)。
  • OLE期间37%(44/119)患者停用或减少背景免疫抑制治疗。

关键数值与推荐

  • 依库珠单抗维持剂量为1200 mg/2周(经盲法诱导期后)。

临床怎么用

  • 对于AQP4-IgG阳性NMOSD患者,依库珠单抗长期治疗可考虑用于降低复发风险,需监测感染等不良事件。

局限性

  • 为开放标签扩展研究的中期分析,非随机对照,长期数据仍需进一步随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD). We report an interim analysis of PREVENT's ongoing open-label extension (OLE; NCT02003144) evaluating eculizumab's long-term safety and efficacy. METHODS: Patients who completed PREVENT could enroll in the OLE to receive eculizumab (maintenance dose = 1,200 mg/2 weeks, after a blinded induction phase). Safety and efficacy data from PREVENT and its OLE (interim data cut, July 31, 2019) were combined for this analysis. RESULTS: Across PREVENT and the OLE, 137 patients received eculizumab and were monitored for a median (range) of 133.3 weeks (5.1-276.9 weeks), for a combined total of 362.3 patient-years (PY). Treatment-related adverse event (AE) and serious adverse event (SAE) rates were 183.5 in 100 PY and 8.6 in 100 PY, respectively. Serious infection rates were 10.2 in 100 PY in eculizumab-treated patients versus 15.1 in 100 PY in the PREVENT placebo group. No patient developed a meningococcal infection. At 192 weeks (3.7 years), 94.4% (95% confidence interval [CI], 88.6-97.3) of patients remained adjudicated relapse-free. The adjudicated annualized relapse rate was 0.025 (95% CI = 0.013-0.048) in all eculizumab-treated patients versus 0.350 (95% CI = 0.199-0.616) in the PREVENT placebo group. During the OLE, 37% of patients (44 of 119 patients) stopped or decreased background immunosuppressive therapy use. INTERPRETATION: This analysis demonstrates that eculizumab's long-term safety profile in NMOSD is consistent with its established profile across other indications. This analysis also demonstrated the sustained ability of long-term eculizumab treatment to reduce relapse risk in patients with AQP4-IgG+ NMOSD. ANN NEUROL 2021;89:1088-1098.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Wingerchuk DM, Fujihara K, Palace J, et al. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol. 2021. PMID: 33586143. doi:10.1002/ana.26049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。